The Cdc42 effector and non-receptor tyrosine kinase, ACK defines a distinct STAT5 transcription signature in a chronic myeloid leukaemia cell model
J. Corry, D. Jachimowicz, B. Keith, J. J. Vicente-Garcia, H. R. Mott, K. Wickson, D. Owen
The paper shows ACK enhances STAT5 transcriptional activity in K562 cells and identifies an ACK-driven STAT5 signature, suggesting a therapeutic target in CML.
bioRxiv · Jun 10, 2022 · PreprintBiochemistry